Wellgistics Health, INC 8-K filings

DataMeds AI, Inc. has entered into a material intellectual property license agreement and taken steps to regain compliance with Nasdaq's minimum stockholders equity requirement.

DataMEDS AI, Inc. announced the settlement of ongoing litigation and the acquisition of a care management platform, bolstering its equity and strategic capabilities.

DataMEDS AI, Inc. has entered into a settlement agreement to resolve ongoing litigation, involving a cash payment for share repurchase and the extinguishment of significant liabilities.

DataMeds AI, Inc. has acquired Helomics Corporation, a cancer diagnostics lab and CRO, for $1.5 million in shares and a convertible note, aiming to expand its services into oncology.

DataMeds AI announced its second quarter 2026 financial results, reporting a 14% sequential revenue increase to $1.779 million but a significant rise in net operating loss to $18.363 million.

Wellgistics Health, Inc. has officially changed its corporate name to DataMeds AI, Inc., and will trade under the new symbol MEDS on the Nasdaq Capital Market starting July 22, 2026.

Wellgistics Health secured a Nasdaq compliance extension for stockholders' equity while confirming it has regained minimum bid price compliance.

Wellgistics Health announced the refinancing of its outstanding convertible debt and a $6.5 million capital raise, satisfying a key condition for a strategic transaction.

Wellgistics Health, Inc. has entered into a securities purchase agreement to raise $16.9 million in gross proceeds through the issuance of convertible promissory notes and warrants.

Wellgistics Health outlines a strategic shift towards vertical integration and blockchain technology to create essential healthcare infrastructure, enhancing efficiency and trust.

Wellgistics Health announces a significant strategic transaction involving multiple entities, aiming to create a new company valued at approximately $4 billion, alongside a 1-for-50 reverse stock split.

Wellgistics Health announced its first quarter 2026 financial results, highlighting sequential revenue growth and strategic advancements in its pharmacy and technology integration efforts.

Wellgistics Health, Inc. announced it will release its first quarter 2026 financial results after market close on Tuesday, May 19, 2026.

Wellgistics Health, Inc. has withdrawn its preliminary proxy statement as it evaluates potential strategic transactions, with the possibility of refiling later.

Wellgistics Health, Inc. has entered into a forbearance agreement with Marco Capital, Inc. to manage approximately $1.77 million in outstanding debt.

Wellgistics Health, Inc. files an amendment to its Form 8-K to correct the reporting date and clarify a material definitive agreement.

Wellgistics Health has entered a joint venture with Kare Rx Hub while simultaneously receiving a Nasdaq delisting notice for failing to meet minimum equity requirements.

Wellgistics Health has entered into a joint venture with Kare Rx Hub to integrate AI-driven technology and expand its pharmaceutical access platform to over 200,000 patient lives.

Wellgistics Health, Inc. has terminated its settlement agreement with Silverback Capital Inc., ceasing further share issuances and pursuing alternative strategic and financing initiatives.

Wellgistics Health, Inc. has entered into a note purchase agreement to issue up to $1.25 million in promissory notes with a 20% original issue discount, maturing in 12 months or upon a qualified financing event.

Wellgistics Health secured court approval for a settlement agreement to resolve over $10.7 million in liabilities by issuing common stock and expanded its partnership with Tollo Health to integrate telehealth and mental health AI capabilities.

Wellgistics Health announced a partnership with NFL Alumni Health to deploy its AI and blockchain technology to improve health outcomes for former NFL players and rural communities.

Wellgistics Health, Inc. announced the immediate resignations of two board directors, Steven Lee and Howard Doss, citing no disagreements with company operations.

Wellgistics Health, Inc. announced a private offering of $8.125 million in secured convertible promissory notes at a 20% original issue discount, raising $6.5 million in cash.

Wellgistics Health, Inc. has secured a private offering of up to $3.125 million in convertible promissory notes to fund its 2026 strategic growth initiatives, focusing on AI platform integration and pharmacy network expansion.

Wellgistics Health announced a December 19, 2025 record date for shareholders to receive one Dream Bowl 2026 Meme Coin token for each share of common stock owned.

Wellgistics Health, Inc. received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price, initiating a 180-day compliance period.

Wellgistics Health announces the commercial launch of its diabetes drug Brenzavvy to its 6,500+ pharmacy network, targeting the $16 billion SGLT-2 inhibitor market.

Wellgistics Health announced a record date for stockholders to receive one Dream Bowl 2026 Meme Coin for each share owned.

Wellgistics Health announces a $250,000 sponsorship of Dream Bowl 2026 and a unique Meme Coin distribution plan for shareholders.